Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 pediatric SLE study of intravenous anifrolumab versus placebo on background standard therapy
CTR20241531Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Anifrolumab IV plus background standard therapy with Placebo IV plus background standard therapy (2 arms). Primary endpoints: Part A: pharmacokinetic characterization and dose determination of anifrolumab and Part B: BICLA response. Started Jan 2025; status: active.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20241531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241531.